收藏切换
Analysis and suggestions for the FDA drug labeling rules on cardiac safety risk warnings
收藏切换
PDF
Wei LIU1a, 2, Xiao-qing XING1a, 3, Yu-qing REN1a, Qian SHEN1a, 4, Yue ZHOU1a, 5, Nan ZHANG1a, 6, Fu-meng LIANG1c, Fang-fang WANG1b, 1c, Hai-yan LI1b, 1c
Chinese Journal of Clinical Pharmacology | 2025, 41(2) : 235 - 239
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(2): 235-239
Reader’s Field
Analysis and suggestions for the FDA drug labeling rules on cardiac safety risk warnings
Full
Wei LIU1a, 2, Xiao-qing XING1a, 3, Yu-qing REN1a, Qian SHEN1a, 4, Yue ZHOU1a, 5, Nan ZHANG1a, 6, Fu-meng LIANG1c, Fang-fang WANG1b, 1c, Hai-yan LI1b, 1c
Affiliations
  • 1a.Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
  • 1b.Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
  • 1c.Department of Cardiology and Institute of Vascular Medicine, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing 100191, China
  • 2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
  • 3.Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050057, Hebei Province, China
  • 4.Department of Pharmacy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
  • 5.Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
  • 6.Department of Pharmacy, The Fifth Clinical Medical College of Henan University of Chinese Medicine / Zhengzhou People’s Hospital, Zhengzhou 450003, Henan Province, China
Published: 2025-01-28 doi: 10.13699/j.cnki.1001-6821.2025.02.017
Outline
收藏切换
Objective

To improve and refine the relevant regulations and guiding principles of warnings on drug instructions and labels in China.

Methods

This paper sorted out the drug instructions of small molecule anti-tumor drugs listed by the U.S. Food and Drug Administration (FDA) from 2005 to 2022, included the drugs mentioned in the QT interval prolongation risk, analyzed the clinical research and QT research results, and sorted out the identification and warning rules of the instructions.

Results

A total of 35 drugs were included, 4 drugs wrote the risk of QT interval prolongation in the black box warning, 21 drugs were wrote in the warning and precautions position, 6 drugs were wrote in the adverse reaction section, and 2 drugs were only described under clinical pharmacology section. According to the severity of the QT interval prolongation caused by the drug and whether there were serious clinical consequences, they were displayed in the warnings (black box warnings), precautions (warnings and precautions) and adverse reactions in the instructions.

Conclusion

The aim of this article is to provide a reference for the writing of QT risk warning information of the instructions of domestic drug production enterprises and regulatory departments. It is recommended to clarify the severity of drug safety and the location of the instructions in clinical research, and continue to carry out safety monitoring and update the instructions in time after listing.

oncology drug  /  drug label  /  QT interval prolongation  /  cardiac safety  /  warning information
Wei LIU, Xiao-qing XING, Yu-qing REN, Qian SHEN, Yue ZHOU, Nan ZHANG, Fu-meng LIANG, Fang-fang WANG, Hai-yan LI. Analysis and suggestions for the FDA drug labeling rules on cardiac safety risk warnings[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (2) : 235 -239 . DOI: 10.13699/j.cnki.1001-6821.2025.02.017
Year 2025 volume 41 Issue 2
PDF
0
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.02.017
  • Receive Date:2024-07-16
  • Online Date:2026-08-04
  • Published:2025-01-28
Article Data
Affiliations
History
  • Received:2024-07-16
Funding
Affiliations
    1a.Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
    1b.Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
    1c.Department of Cardiology and Institute of Vascular Medicine, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing 100191, China
    2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
    3.Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050057, Hebei Province, China
    4.Department of Pharmacy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
    5.Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
    6.Department of Pharmacy, The Fifth Clinical Medical College of Henan University of Chinese Medicine / Zhengzhou People’s Hospital, Zhengzhou 450003, Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.02.017
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT